FIG 9.
Postchallenge survival of cynomolgus macaques immunized with the trivalent rVSV-N4CT1 pan-FiloGP1 vaccine. At study day 0, macaques were immunized i.m. with 3 × 107 PFU of the trivalent rVSV-N4CT1 pan-FiloGP1 vaccine. As a control, macaques were immunized with 3 × 107 PFU of an rVSV-N4CT1gag1 vector. At study day 28, the macaques were challenged i.m. with 1,000 PFU 7U EBOV Kikwit (A), SUDV Gulu (B), or MARV Angola (C).